The present invention provides a method for selective delivery of a therapeutic or diagnostic agent to a targeted organ or tissue by implanting a biocompatible solid support in the patient being linked to a first binding agent, and administering a second binding agent to the patient linked to the therapeutic or diagnostic agent, such that the therapeutic or diagnostic agent accumulates at the targeted organ or tissue.

The present invention provides a method for selective delivery of a therapeutic or diagnostic agent to a targeted organ or tissue by implanting a biocompatible solid support in the patient being linked to a first binding agent, and administering a second binding agent to the patient linked to the therapeutic or diagnostic agent, such that the therapeutic or diagnostic agent accumulates at the targeted organ or tissue.

Disclosed are C-glycoside amine derivatives of the formula:

RCH.sub.2C(CH.sub.3)NHR.sub.2

wherein R is a saccharide (e.g., as described in U.S. Pat. No. 8,314,219) and R.sub.2 is an acyl moiety derived from any ketone of the formula R.sub.3C(O)R.sub.3 wherein R.sub.3 is C1 to C22 straight or branched chain hydrocarbon which may be saturated or unsaturated. In addition, a method for making the C-glycoside amine derivatives involving (1) reacting a saccharide (e.g., glucose) C-glycoside ketone with a catalyst (e.g., Rh), about 10 to about 25 fold excess NH.sub.3, and an organic solvent (e.g., methanol) to form a saccharide C-glycoside amine, and (2) reacting said saccharide C-glycoside amine with a catalyst (e.g., Rh), an organic solvent (e.g., methanol), and an acyl moiety derived from any ketone of the formula R.sub.3C(O)R.sub.3 wherein R.sub.3 is C1 to C22 straight or branched chain hydrocarbon which may be saturated or unsaturated to form said C-glycoside amine derivative.

Disclosed are C-glycoside amine derivatives of the formula:

RCH.sub.2C(CH.sub.3)NHR.sub.2

wherein R is a saccharide (e.g., as described in U.S. Pat. No. 8,314,219) and R.sub.2 is an acyl moiety derived from any ketone of the formula R.sub.3C(O)R.sub.3 wherein R.sub.3 is C1 to C22 straight or branched chain hydrocarbon which may be saturated or unsaturated. In addition, a method for making the C-glycoside amine derivatives involving (1) reacting a saccharide (e.g., glucose) C-glycoside ketone with a catalyst (e.g., Rh), about 10 to about 25 fold excess NH.sub.3, and an organic solvent (e.g., methanol) to form a saccharide C-glycoside amine, and (2) reacting said saccharide C-glycoside amine with a catalyst (e.g., Rh), an organic solvent (e.g., methanol), and an acyl moiety derived from any ketone of the formula R.sub.3C(O)R.sub.3 wherein R.sub.3 is C1 to C22 straight or branched chain hydrocarbon which may be saturated or unsaturated to form said C-glycoside amine derivative.

The present invention provides a novel process for preparing an oligosaccharide C-glycoside derivative of formula I, comprising reacting a compound of formula II with compound of formula III in the presence of at least one primary or secondary amine and at least one additive [in the formulae, the substituents are as defined herein], and novel oligosaccharide C-glycoside derivatives that can be prepared using the process.

##STR00001##

The present invention provides sialic acid analogs and their compositions useful for the treatment of sialic acid deficiencies.

The present invention provides sialic acid analogs and their compositions useful for the treatment of sialic acid deficiencies.

Embodiments of the present disclosure provide for labeled probes such as labeled maltoside probes and labeled maltotriose probes, methods of making labeled probes, pharmaceutical compositions including labeled probes, methods of using labeled probes, methods of diagnosing, localizing, monitoring, and/or assessing bacterial infections, using labeled probes, kits for diagnosing, localizing, monitoring, and/or assessing bacterial infections, using labeled probes, and the like.

Embodiments of the present disclosure provide for labeled probes such as labeled maltoside probes and labeled maltotriose probes, methods of making labeled probes, pharmaceutical compositions including labeled probes, methods of using labeled probes, methods of diagnosing, localizing, monitoring, and/or assessing bacterial infections, using labeled probes, kits for diagnosing, localizing, monitoring, and/or assessing bacterial infections, using labeled probes, and the like.

The present invention relates to novel inhibitors of the shikimate pathway (shikimic acid pathway), pharmaceutical compositions comprising these novel inhibitors, methods for the production of the inhibitors and their use as antibiotics and herbicides.